Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsEfficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSEstablishing equivalence or non-inferiority in clinical trials: part 20 of a series on evaluation of scientific publicationsNovel therapeutic strategies targeting HIV integraseThe ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?Long-term efficacy and safety of raltegravir in the management of HIV infection.Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trialsClinical use of HIV integrase inhibitors: a systematic review and meta-analysisEffectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed ViremiaSwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.HIV integrase inhibitors: a new era in the treatment of HIV.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood ProductsUrinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysisProtease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapyEffects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular studyTreatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study.Role of raltegravir in the management of HIV-1 infection.Switching antiretroviral therapy to minimize metabolic complications.Management of dyslipidemia in HIV-infected patients.Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.Long-term safety from the raltegravir clinical development program.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.Antiretroviral drugs: critical issues and recent advancesManagement of the metabolic effects of HIV and HIV drugs.Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.
P2860
Q24628743-AEB346BB-4AB0-4233-A69C-DBAF75B2505BQ26783253-D0EE1E74-0225-48AB-9A74-089068CE848AQ27002507-5ADA0933-FB0F-4BA4-BBE8-0F086C428BD0Q27003960-FC9F9F55-35F4-4B43-8645-01BBD2F1B2C4Q27030892-996850C5-CD94-4AE0-9C6D-BAEE1B1F6135Q27686870-9BBE8273-79B8-4706-8272-1000AD44867DQ28476822-1E5410FD-F4A8-47EA-8ABB-AC328990B779Q28484930-74C29FD5-C7A7-4A21-B2BF-A8970F3E6530Q28548630-ABC8A409-5474-4895-A81E-766C31DFECD4Q28553066-52ADBE23-A499-4845-B846-E39F5FCE94B4Q28553571-BCDF06C4-8973-46F0-AE12-C887EE07F61BQ30355190-269F00AC-AB29-484D-911B-30E72DFBC8D5Q30815467-0C824986-FC11-49BA-8574-CC69B471A7F3Q30956943-A702764E-0607-4261-B13D-13132409503CQ33557819-854BA0EB-6F6A-4C00-BA7C-D92AB5A981FAQ33668385-6DF0BF2D-716B-4FAA-9157-FF1CDE1F228EQ33759853-54F9EDA2-CEFE-4045-9709-FB8DDF73DD1FQ33775397-4F3007A7-54DC-4BB1-9B99-D1147522299CQ33934080-D0BB7866-2963-4406-9699-D8C44B94DC6AQ33945171-0846C2F4-2B5F-4EC3-9F4E-68326A7C8B23Q34518299-D014C6A2-9387-4722-AC6F-88AF3253FE14Q34631149-F98AF1ED-3017-47BC-93C4-CA42941E301CQ34713094-86E63A84-AF35-4463-8BE9-57992B689D70Q34730407-ABC6CA61-03F3-4E3F-962A-9EA0488BA912Q34736194-F84076A3-2A21-4A60-88C9-9ABEF47D5150Q35023687-A3EF6632-6DA4-40EA-B3C1-D4E84245FB46Q35026582-F0290A92-7CBF-4857-A01F-B64BFEBF61F3Q35106654-363B0911-BF2C-4B2C-8CAA-7FF6F41D242EQ35147189-3203C14A-6899-4115-9F47-605788A07410Q35175902-3C570DD7-88CB-4D72-974A-E52B6111F2B3Q35557318-2B91DCFA-B012-4A77-B46E-C538E83EC2CBQ35608074-7452D680-59AA-4921-81C7-4F41B4406D68Q35643573-AD087E56-7D1A-4030-AEB8-145BD5C64117Q35693353-D4BE16F7-D2C7-40BD-A600-C6E4014ADFC1Q35701258-F8F6D71F-1828-4C4B-A2DA-00DDBF375FFAQ35789343-55DC200D-C902-4FE7-BBC1-97A3A190FD75Q35896106-395EB431-D8DB-464A-871B-00E505E63386Q36020992-4B76242C-7A3D-41F7-85ED-5936CDF59431Q36021411-636D4895-791E-430E-ADE2-8D8AFA04EAFAQ36051942-B145C1C2-1400-4813-B9ED-A11695221F60
P2860
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Switch to a raltegravir-based ...... randomised controlled trials.
@en
Switch to a raltegravir-based ...... randomised controlled trials.
@nl
type
label
Switch to a raltegravir-based ...... randomised controlled trials.
@en
Switch to a raltegravir-based ...... randomised controlled trials.
@nl
prefLabel
Switch to a raltegravir-based ...... randomised controlled trials.
@en
Switch to a raltegravir-based ...... randomised controlled trials.
@nl
P2093
P1433
P1476
Switch to a raltegravir-based ...... randomised controlled trials.
@en
P2093
Anthony J Rodgers
Bach-Yen Nguyen
Benjamin Young
Cassy Workman
Daniel S Berger
David A Cooper
Edwin Dejesus
Jaime Andrade-Villanueva
Mark J Dinubile
Melissa A Shaughnessy
P304
P356
10.1016/S0140-6736(09)62041-9
P407
P577
2010-01-12T00:00:00Z